Yale-new Haven Hospital
- Type
- Teaching hospital
- Where
- New Haven, CT
- Medicare CCN
- 070022
- Received
- $2,426,488 in 170 records, 2024 ($328,526 general, $2,097,962 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Nonprofit contractor: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Plan sponsor: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Federal award recipient: YALE NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying client: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Lobbying client: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying registrant: YALE-NEW HAVEN HOSPITAL Fuzzy (name and state)
- Nonprofit: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 92 | $328,526 |
| 2024 | Research payment | 78 | $2,097,962 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 78 | $2,097,962 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 18 | $155,567 |
| Space rental or facility fees (teaching hospital only) | 9 | $53,000 |
| Long term medical supply or device loan | 8 | $42,514 |
| Grant | 7 | $31,620 |
| Debt forgiveness | 15 | $27,134 |
| Education | 28 | $11,700 |
| Charitable Contribution | 6 | $5,475 |
| Royalty or License | 1 | $1,514 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $49,706 | Research payment | In-kind items and services | Biograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | Enhancing Corrections for Cardiac PETCT in Infiltrative Cardiomyopathy | 2024 |
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $37,856 | Research payment | In-kind items and services | Biograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | Personalized Task based Respiratory Motion Correction for Low Dose | 2024 |
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $32,159 | Research payment | In-kind items and services | Biograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | PETCT Imaging of Peripheral Arterial Disease | 2024 |
| 2024-12-31 | Diagnostica Stago, Inc | $16,859 | Research payment | In-kind items and services | ST GENESIA Device, global hemostasis | Catheter-Related Early Thromboprophylaxis with Enoxaparin (CRETE) Studies | 2024 |
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $14,383 | Research payment | In-kind items and services | Biograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | Right Ventricular RV Hemodynamics in Patients with Sleep Apnea to Guide Therapy | 2024 |
| 2024-12-31 | Stryker Corporation | $2,394 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $2,394 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $796 | Long term medical supply or device loan | In-kind items and services | NA Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-20 | SANOFI US SERVICES INC. | $200 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-12-19 | BeiGene, Ltd. | $10,408 | Research payment | In-kind items and services | TEVIMBRA Drug, Oncology | Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-B1 | 2024 |
| 2024-12-18 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, VASCULAR | ECLIPSE | 2024 |
| 2024-12-16 | Olympus America Inc. | $0 | Debt forgiveness | In-kind items and services | EVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-12-10 | ABBVIE INC. | $129,743 | Research payment | In-kind items and services | ELAHERE Drug, ONCOLOGY | MIRV/carboplatin neo-adjuvant therapy in newly diagnosed ovarian cancer | 2024 |
| 2024-12-05 | Bracco Diagnostics Inc. | $170,937 | Research payment | Cash or cash equivalent | ProHance Drug, Diagnostic Imaging | AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVED | 2024 |
| 2024-11-21 | PFIZER INC. | $37,012 | Research payment | Cash or cash equivalent | NHCRU YNH INVOICES MAYSEP | 2024 | |
| 2024-11-21 | Siemens Medical Solutions USA, Inc. | $3,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-11-18 | Draeger Medical Systems, Inc | $32,189 | Research payment | Cash or cash equivalent | STIMIT Activator 1 Pivotal Study | 2024 | |
| 2024-11-18 | Draeger Medical Systems, Inc | $3,923 | Research payment | Cash or cash equivalent | STIMIT Activator 1 Pivotal Study | 2024 | |
| 2024-11-14 | TransMedics, Inc. | $1,200 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCSHEART-01-ClinPAS | 2024 |
| 2024-11-08 | BeiGene, Ltd. | $20,816 | Research payment | In-kind items and services | TEVIMBRA Drug, Oncology | Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-B1 | 2024 |
| 2024-11-08 | TransMedics, Inc. | $20,388 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCSHEART-OHP-II | 2024 |
| 2024-11-08 | TransMedics, Inc. | $1,800 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCSHEART-OHP-II | 2024 |
| 2024-11-06 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-10-29 | Servier BioInnovation | $198,925 | Research payment | In-kind items and services | Tibsovo Drug, Oncology | PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATI | 2024 |
| 2024-10-29 | Abbott Laboratories | $650 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, VASCULAR | ECLIPSE | 2024 |
| 2024-10-25 | National Marrow Donor Program | $15,095 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-10-15 | KLS-Martin L.P. | $11,402 | Debt forgiveness | Cash or cash equivalent | IPS, IMPLANT, CRANIAL, 00087, CP TITANIUM, QTY: 001 EA Device, Osteosynthesis | 2024 | |
| 2024-10-15 | KLS-Martin L.P. | $1,975 | Debt forgiveness | Cash or cash equivalent | IPS, SUPPLEMENTAL MODEL, FULL, 00007, QTY: 001 EA Device, Osteosynthesis | 2024 | |
| 2024-10-09 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-10-02 | SERVIER PHARMACEUTICALS LLC | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-10-02 | Becton, Dickinson and Company | $50 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-09-27 | Olympus America Inc. | $0 | Debt forgiveness | In-kind items and services | EVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-09-26 | Sage Therapeutics, LLC | $59,600 | Research payment | Cash or cash equivalent | ZULRESSO Drug, PSYCHIATRY/PSYCHOLOGY | Utility of Brexanolone to target stress-induced alcohol use among men and women with Posttraumatic Stress Disorder | 2024 |
| 2024-09-25 | Organon Llc | $1,400 | Long term medical supply or device loan | In-kind items and services | JADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING | 2024 | |
| 2024-09-25 | Barco, Inc. | $1,005 | Long term medical supply or device loan | In-kind items and services | 2024 | ||
| 2024-09-19 | BeiGene, Ltd. | $31,224 | Research payment | In-kind items and services | TEVIMBRA Drug, Oncology | Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-B1 | 2024 |
| 2024-09-13 | Siemens Medical Solutions USA, Inc. | $1,514 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-09-10 | BeiGene, Ltd. | $10,408 | Research payment | In-kind items and services | TEVIMBRA Drug, Oncology | Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-B1 | 2024 |
| 2024-09-04 | Takeda Pharmaceuticals U.S.A., Inc. | $8,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-09-01 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-08-31 | Regeneron Pharmaceuticals, Inc. | $100 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-08-29 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-08-28 | ABBVIE INC. | $64,871 | Research payment | In-kind items and services | ELAHERE Drug, ONCOLOGY | MIRV/carboplatin neo-adjuvant therapy in newly diagnosed ovarian cancer | 2024 |
| 2024-08-27 | Beckman Coulter, Inc. | $136,175 | Research payment | Cash or cash equivalent | Triage Clinical Decision Support Impact Study | 2024 | |
| 2024-08-27 | E.R. Squibb & Sons, L.L.C. | $13,928 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibr | 2024 | |
| 2024-08-23 | Eisai Inc. | $125 | Education | Cash or cash equivalent | 2024 | ||
| 2024-08-22 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-08-21 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-08-15 | PFIZER INC. | $43,900 | Research payment | Cash or cash equivalent | NHCRU YNH INVOICES | 2024 | |
| 2024-08-15 | PFIZER INC. | $5,336 | Research payment | Cash or cash equivalent | A PHASE 1 OPENLABEL RANDOMIZED 5PERIOD 6SEQUENCE CROSSOVER STUDY TO COMPARE THE SINGLEDOSE PHARMACOKINETICS OF IMMEDIATE | 2024 | |
| 2024-08-15 | Medical Device Business Services, Inc. | $1,004 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-08-06 | ABBVIE INC. | $64,871 | Research payment | In-kind items and services | ELAHERE Drug, ONCOLOGY | MIRV/carboplatin neo-adjuvant therapy in newly diagnosed ovarian cancer | 2024 |
| 2024-07-30 | United Imaging Healthcare North America, Inc. | $227,227 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-07-26 | National Marrow Donor Program | $18,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-24 | ARGENX US, INC. | $99,064 | Research payment | Cash or cash equivalent | AChR autoantibody-mediated complement activity in MG patients | 2024 | |
| 2024-07-24 | Alexion Pharmaceuticals, Inc. | $70 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-15 | Draeger Medical Systems, Inc | $1,500 | Research payment | Cash or cash equivalent | STIMIT Activator 1 Pivotal Study | 2024 | |
| 2024-07-12 | Siemens Medical Solutions USA, Inc. | $6,230 | Research payment | Cash or cash equivalent | Atellica IM AMH Analytical and Clinical Study | 2024 | |
| 2024-07-10 | ARGENX US, INC. | $49,532 | Research payment | Cash or cash equivalent | AChR autoantibody-mediated complement activity in MG patients | 2024 | |
| 2024-07-10 | PFIZER INC. | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-10 | PFIZER INC. | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-10 | PFIZER INC. | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-10 | PFIZER INC. | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-05 | TransMedics, Inc. | $9,854 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCSHEART-01-ClinPAS | 2024 |
| 2024-07-05 | TransMedics, Inc. | $849 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCSHEART-01-ClinPAS | 2024 |
| 2024-07-04 | Karyopharm Therapeutics Inc. | $19,500 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2024 |
| 2024-07-04 | Karyopharm Therapeutics Inc. | $5,000 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2024 |
| 2024-07-04 | Karyopharm Therapeutics Inc. | $5,000 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2024 |
| 2024-07-04 | Karyopharm Therapeutics Inc. | $3,000 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2024 |
| 2024-07-04 | Karyopharm Therapeutics Inc. | $2,500 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2024 |
| 2024-07-04 | Karyopharm Therapeutics Inc. | $1,800 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2024 |
| 2024-07-04 | Karyopharm Therapeutics Inc. | $1,215 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2024 |
| 2024-07-04 | Karyopharm Therapeutics Inc. | $994 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2024 |
| 2024-06-27 | ARRAY BIOPHARMA INC | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-06-25 | Biogen, Inc. | $5,819 | Research payment | Cash or cash equivalent | A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON) | 2024 | |
| 2024-06-25 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-06-24 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, VASCULAR | ECLIPSE | 2024 |
| 2024-06-24 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, VASCULAR | ECLIPSE | 2024 |
| 2024-06-24 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, VASCULAR | ECLIPSE | 2024 |
| 2024-06-14 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-06-14 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-06-10 | E.R. Squibb & Sons, L.L.C. | $3,600 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-06-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-06-04 | PFIZER INC. | $75 | Education | In-kind items and services | 2024 | ||
| 2024-06-03 | PFIZER INC. | $75 | Education | In-kind items and services | 2024 | ||
| 2024-05-31 | Regeneron Pharmaceuticals, Inc. | $25 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-05-29 | Alexion Pharmaceuticals, Inc. | $70 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-05-28 | Draeger Medical Systems, Inc | $1,355 | Research payment | Cash or cash equivalent | STIMIT Activator 1 Pivotal Study | 2024 | |
| 2024-05-20 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-05-17 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-05-17 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-05-16 | PFIZER INC. | $27,215 | Research payment | Cash or cash equivalent | A PHASE 1 RANDOMIZED OPENLABEL 3PERIOD CROSSOVER SINGLEDOSE 2PART STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE EFFEC | 2024 | |
| 2024-05-15 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-05-15 | Alexion Pharmaceuticals, Inc. | $140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-05-14 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-05-14 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-05-14 | PFIZER INC. | $125 | Education | In-kind items and services | 2024 | ||
| 2024-05-10 | Siemens Medical Solutions USA, Inc. | $12,460 | Research payment | Cash or cash equivalent | Atellica IM 1300 Analyzer Device, DX - Diagnostics incl. all products and services | Atellica IM AMH Analytical and Clinical Study | 2024 |
| 2024-05-10 | McKesson Drug Company LLC | $5,000 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-05-06 | PFIZER INC. | $50 | Education | In-kind items and services | 2024 | ||
| 2024-05-02 | E.R. Squibb & Sons, L.L.C. | $15,035 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibro | 2024 | |
| 2024-04-30 | Regeneron Pharmaceuticals, Inc. | $100 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-04-29 | KLS-Martin L.P. | $7,796 | Debt forgiveness | Cash or cash equivalent | IPS, IMPLANT, CRANIAL, 00089, CP TITANIUM, QTY: 001 EA Device, Osteosynthesis | 2024 | |
| 2024-04-29 | PFIZER INC. | $5,113 | Research payment | Cash or cash equivalent | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED CROSSOVER FIRSTINHUMAN STUDY TO ASSESS THE SAFETY TOLERAB | 2024 | |
| 2024-04-29 | KLS-Martin L.P. | $2,195 | Debt forgiveness | Cash or cash equivalent | IPS, SUPPLEMENTAL MODEL, FULL, 00007, QTY: 001 EA Device, Osteosynthesis | 2024 | |
| 2024-04-28 | PFIZER INC. | $100 | Education | In-kind items and services | 2024 | ||
| 2024-04-26 | National Marrow Donor Program | $9,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-04-24 | Alexion Pharmaceuticals, Inc. | $72 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-04-19 | National Marrow Donor Program | $5,500 | Research payment | Cash or cash equivalent | A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for N | 2024 | |
| 2024-04-19 | PFIZER INC. | $4,000 | Education | In-kind items and services | 2024 | ||
| 2024-04-18 | E.R. Squibb & Sons, L.L.C. | $10,000 | Grant | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-04-18 | E.R. Squibb & Sons, L.L.C. | $5,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-04-10 | PFIZER INC. | $45,591 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-04-10 | M.A. Med Alliance S.A. | $1,800 | Research payment | Cash or cash equivalent | SELUTION SLR DEB 014 Device, CARDIOVASCULAR | A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR 014 | 2024 |
| 2024-04-09 | Incyte Corporation | $5,000 | Education | Cash or cash equivalent | 2024 | ||
| 2024-04-02 | E.R. Squibb & Sons, L.L.C. | $33,714 | Research payment | Cash or cash equivalent | SOTYKTU Drug, Immunology | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With SLE | 2024 |
| 2024-04-01 | PFIZER INC. | $100 | Education | In-kind items and services | 2024 | ||
| 2024-04-01 | PFIZER INC. | $75 | Education | In-kind items and services | 2024 | ||
| 2024-03-29 | TransMedics, Inc. | $250 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCS-CAR-03202019 | 2024 |
| 2024-03-27 | Alexion Pharmaceuticals, Inc. | $35 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-03-25 | Gen-Probe, Inc. | $28,205 | Research payment | Cash or cash equivalent | PANTHER FUSION Device, Diagnostics | Method Comparison Study Protocol for the Panther Fusion GI Panels | 2024 |
| 2024-03-21 | E.R. Squibb & Sons, L.L.C. | $13,097 | Research payment | Cash or cash equivalent | Phase I/II FIH Monotherapy/Combination | 2024 | |
| 2024-03-20 | Boston Scientific Corporation | $20,342 | Long term medical supply or device loan | In-kind items and services | AVVIGO Guidance System Device, AVVIGO Guidance System | 2024 | |
| 2024-03-20 | Amgen Inc. | $842 | Research payment | In-kind items and services | IMDELLTRA (AMG757) Biological, Hematology | P3 LS-SCLC Mono 757 vs Placebo | 2024 |
| 2024-03-13 | Intuitive Surgical, Inc. | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DA VINCI SP Device, SURGERY | 2024 | |
| 2024-03-13 | Alexion Pharmaceuticals, Inc. | $105 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-03-12 | Caption Health, Inc. | $53,504 | Research payment | Cash or cash equivalent | Device, Lung Guidance | Lung Guidance | 2024 |
| 2024-03-06 | PFIZER INC. | $50 | Education | In-kind items and services | 2024 | ||
| 2024-03-05 | Genentech USA, Inc. | $15,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Phesgo Biological, BioOncology | 2024 | |
| 2024-03-01 | E.R. Squibb & Sons, L.L.C. | $1,365 | Research payment | Cash or cash equivalent | SOTYKTU Drug, Immunology | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With SLE | 2024 |
| 2024-02-29 | Novartis Pharmaceuticals Corporation | $21,018 | Research payment | Cash or cash equivalent | KISQALI Drug, Oncology | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | 2024 |
| 2024-02-27 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, VASCULAR | ECLIPSE | 2024 |
| 2024-02-26 | Novartis Pharmaceuticals Corporation | $4,680 | Research payment | In-kind items and services | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety an | 2024 | |
| 2024-02-22 | Barco, Inc. | $1,991 | Long term medical supply or device loan (2 payments) | In-kind items and services | 2024 | ||
| 2024-02-21 | Eisai Inc. | $5,000 | Grant | Cash or cash equivalent | Lenvima Drug, Oncology | 2024 | |
| 2024-02-21 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | 2024 | |
| 2024-02-21 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, VASCULAR | ECLIPSE | 2024 |
| 2024-02-20 | PFIZER INC. | $25,402 | Research payment | Cash or cash equivalent | A MULTIPART PHASE 1 STUDY WITH RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED SINGLE AND MULTIPLEDOSE ESCALATION T | 2024 | |
| 2024-02-20 | Abbott Laboratories | $1,300 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, VASCULAR | ECLIPSE | 2024 |
| 2024-02-15 | Medical Device Business Services, Inc. | $4,016 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-02-15 | Olympus America Inc. | $280 | Debt forgiveness | In-kind items and services | RHINO-LARYNGO VIDEOSCOPE Device, Ear, Nose, Throat | 2024 | |
| 2024-02-12 | PFIZER INC. | $75 | Education | In-kind items and services | 2024 | ||
| 2024-02-12 | PFIZER INC. | $75 | Education | In-kind items and services | 2024 | ||
| 2024-02-08 | AstraZeneca Pharmaceuticals LP | $25,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-02-06 | Olympus America Inc. | $233 | Debt forgiveness | In-kind items and services | EVES EUS ULTRASOUND BRONCHOFIBERVIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-02-05 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-01-29 | Eli Lilly and Company | $4,638 | Research payment | In-kind items and services | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATI | 2024 | |
| 2024-01-23 | PFIZER INC. | $75 | Education | In-kind items and services | 2024 | ||
| 2024-01-17 | Intuitive Surgical, Inc. | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DA VINCI SP Device, SURGERY | 2024 | |
| 2024-01-12 | National Marrow Donor Program | $16,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-01-12 | Draeger Medical Systems, Inc | $500 | Research payment | Cash or cash equivalent | STIMIT Activator 1 Pivotal Study | 2024 | |
| 2024-01-11 | PFIZER INC. | $75 | Education | In-kind items and services | 2024 | ||
| 2024-01-09 | Novartis Pharmaceuticals Corporation | $684 | Research payment | In-kind items and services | A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients Wit | 2024 | |
| 2024-01-08 | Takeda Pharmaceuticals U.S.A., Inc. | $24,936 | Research payment | Cash or cash equivalent | TAKCLNTRL0000184: External Controls for Clinical Trials | 2024 | |
| 2024-01-08 | Takeda Pharmaceuticals U.S.A., Inc. | $24,936 | Research payment | Cash or cash equivalent | TAKCLNTRL0000184: External Controls for Clinical Trials | 2024 | |
| 2024-01-08 | Takeda Pharmaceuticals U.S.A., Inc. | $24,936 | Research payment | Cash or cash equivalent | TAKCLNTRL0000184: External Controls for Clinical Trials | 2024 | |
| 2024-01-08 | Takeda Pharmaceuticals U.S.A., Inc. | $24,936 | Research payment | Cash or cash equivalent | TAKCLNTRL0000184: External Controls for Clinical Trials | 2024 | |
| 2024-01-03 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-01-03 | Olympus America Inc. | $1,191 | Debt forgiveness | In-kind items and services | GASTROINTESTINAL VIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-01-03 | Olympus America Inc. | $1,000 | Debt forgiveness | In-kind items and services | EVIS X1 VIDEO SYSTEM CENTER Device, Gastroenterology | 2024 | |
| 2024-01-03 | Olympus America Inc. | $544 | Debt forgiveness | In-kind items and services | EVIS EXERA III COLONOVIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-01-03 | Olympus America Inc. | $176 | Debt forgiveness | In-kind items and services | EVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-01-03 | Olympus America Inc. | $166 | Debt forgiveness | In-kind items and services | EVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-01-03 | Olympus America Inc. | $99 | Debt forgiveness | In-kind items and services | EVIS EXERA III COLONOVIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-01-03 | Olympus America Inc. | $72 | Debt forgiveness | In-kind items and services | GASTROINTESTINAL VIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-01-02 | Beckman Coulter, Inc. | $28,885 | Research payment | Cash or cash equivalent | Triage Clinical Decision Support Impact Study | 2024 | |
| 2024-01-01 | ClearPoint Neuro, Inc. | $12,191 | Long term medical supply or device loan | In-kind items and services | CLEARPOINT Device, Neurology | 2024 | |
| 2024-01-01 | Novartis Pharmaceuticals Corporation | $11,140 | Research payment | Cash or cash equivalent | Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investiga | 2024 | |
| 2024-01-01 | Novartis Pharmaceuticals Corporation | $1,770 | Research payment | In-kind items and services | A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax | 2024 | |
| 2024-01-01 | Novartis Pharmaceuticals Corporation | $40 | Research payment | In-kind items and services | A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for th | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) New Haven, CT | County South Central Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 134,349 | 570,598 | 3,624,508 |
| Population, 2020 census P1 | 134,023 | - | 3,605,944 |
| Median age B01002 | 31.9 | 40.2 | 41.1 |
| Under 18 B01001 | 21.3% | 19.6% | 20.2% |
| 65 and over B01001 | 11.8% | 18.6% | 18.5% |
| Households B11001 | 54,773 | 230,673 | 1,434,007 |
| Foreign born B05002 | 18.0% | 13.7% | 15.7% |
| Median household income B19013 | $56,851 | $88,197 | $95,781 |
| Median family income B19113 | $68,668 | $115,384 | $122,706 |
| Per capita income B19301 | $36,242 | $49,766 | $55,915 |
| Poverty rate B17001 | 23.9% | 11.4% | 10.0% |
| Unemployment rate B23025 | 8.4% | 6.0% | 5.6% |
| Civilian labor force B23025 | 69,528 | 307,607 | 1,959,490 |
| Mean commute (minutes) B08013 | 21.5 | 23.5 | 26.5 |
| Bachelor's degree or higher B15003 | 38.9% | 42.0% | 42.5% |
| Housing units B25001 | 60,333 | 248,267 | 1,541,822 |
| Owner-occupied B25003 | 28.4% | 60.5% | 66.5% |
| Renters B25003 | 71.6% | 39.5% | 33.5% |
| Median home value B25077 | $287,100 | $353,100 | $366,900 |
| Median gross rent B25064 | $1,488 | $1,525 | $1,488 |
| White, not Hispanic B03002 | 30.0% | 58.5% | 61.9% |
| Black B03002 | 27.6% | 13.0% | 9.8% |
| Hispanic or Latino B03002 | 31.0% | 19.5% | 18.3% |
| Asian B03002 | 5.2% | 4.5% | 4.7% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.
Comments